FDA Approval Alert: The Need-to-Know | Zanubrutinib/Obinutuzumab for Relapsed/Refractory Follicular Lymphoma

In March 2024, The FDA granted accelerated approval to zanubrutinib plus obinutuzumab for the treatment of patients with relapsed/refractory follicular lymphoma following 2 previous lines of treatment.

Zanubrutinib Combo Could “Prolong Time in Remission” for Follicular Lymphoma
Zanubrutinib Combo Could “Prolong Time in Remission” for Follicular Lymphoma
Video
Mar 7, 2024 10:00 PM
The FDA approval of zanubrutinib plus obinutuzumab showed a benefit to patients with relapsed/refractory follicular lymphoma, according to Julie Vose, MD, MBA.
Patients with relapsed/refractory follicular lymphoma can now receive zanubrutinib plus obinutuzumab based on the data from the phase 2 ROSEWOOD trial.
Zanubrutinib Combo Earns Accelerated Approval for R/R Follicular Lymphoma
Article
Mar 7, 2024 8:44 PM
Patients with relapsed/refractory follicular lymphoma can now receive zanubrutinib plus obinutuzumab based on the data from the phase 2 ROSEWOOD trial.